Literature DB >> 27808481

RNF167 targets Arl8B for degradation to regulate lysosome positioning and endocytic trafficking.

Rakesh Deshar1, Song Moon2, Wonjin Yoo2, Eun-Bee Cho2, Sungjoo K Yoon1, Jong-Bok Yoon2.   

Abstract

The protease-associated (PA) domain-containing E3 ubiquitin ligases are transmembrane proteins located in intracellular organelles such as the endoplasmic reticulum, endosomes, or lysosomes. The functional roles of these ubiquitin ligases are not well defined. To understand the function of E3 ubiquitin ligases, identification of their substrates is of critical importance. In this study, we describe a newly devised method based on proximity-dependent biotin labeling to identify substrates of ubiquitin ligases. Application of this method to RING finger protein 167 (RNF167), a member of the PA domain-containing E3 family, led to identification of Arl8B as its substrate. We demonstrated that RNF167 ubiquitinates Arl8B at the lysine residue K141 and reduces the level of the Arl8B protein. Overexpression and knockdown of RNF167 revealed its regulatory role in Arl8B-dependent lysosome positioning and endocytic trafficking to lysosomes. Furthermore, we found that the ubiquitination-defective Arl8B K141R mutant counteracts RNF167 in these cellular events. These results indicate that RNF167 plays a crucial role as an E3 ubiquitin ligase targeting Arl8B to regulate lysosome positioning and endocytic trafficking.
© 2016 Federation of European Biochemical Societies.

Entities:  

Keywords:  Arl8B; RNF167; endocytosis; lysosome; proteolysis

Mesh:

Substances:

Year:  2016        PMID: 27808481     DOI: 10.1111/febs.13947

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  8 in total

1.  The E3 ubiquitin ligase MARCH2 regulates ERGIC3-dependent trafficking of secretory proteins.

Authors:  Wonjin Yoo; Eun-Bee Cho; Sungjoo Kim; Jong-Bok Yoon
Journal:  J Biol Chem       Date:  2019-05-29       Impact factor: 5.157

2.  RNF43 inhibits WNT5A-driven signaling and suppresses melanoma invasion and resistance to the targeted therapy.

Authors:  Tomasz Radaszkiewicz; Michaela Nosková; Kristína Gömöryová; Olga Vondálová Blanářová; Katarzyna Anna Radaszkiewicz; Markéta Picková; Ráchel Víchová; Tomáš Gybeľ; Karol Kaiser; Lucia Demková; Lucia Kučerová; Tomáš Bárta; David Potěšil; Zbyněk Zdráhal; Karel Souček; Vítězslav Bryja
Journal:  Elife       Date:  2021-10-27       Impact factor: 8.140

Review 3.  Regulation of AMPA Receptor Trafficking by Protein Ubiquitination.

Authors:  Jocelyn Widagdo; Sumasri Guntupalli; Se E Jang; Victor Anggono
Journal:  Front Mol Neurosci       Date:  2017-10-26       Impact factor: 5.639

4.  RNF167 activates mTORC1 and promotes tumorigenesis by targeting CASTOR1 for ubiquitination and degradation.

Authors:  Tingting Li; Xian Wang; Enguo Ju; Suzane Ramos da Silva; Luping Chen; Xinquan Zhang; Shan Wei; Shou-Jiang Gao
Journal:  Nat Commun       Date:  2021-02-16       Impact factor: 14.919

5.  RNF13 Dileucine Motif Variants L311S and L312P Interfere with Endosomal Localization and AP-3 Complex Association.

Authors:  Valérie C Cabana; Antoine Y Bouchard; Audrey M Sénécal; Kim Ghilarducci; Saïd Kourrich; Laurent Cappadocia; Marc P Lussier
Journal:  Cells       Date:  2021-11-06       Impact factor: 6.600

Review 6.  From Drosophila to Human: Biological Function of E3 Ligase Godzilla and Its Role in Disease.

Authors:  Valérie C Cabana; Marc P Lussier
Journal:  Cells       Date:  2022-01-23       Impact factor: 6.600

7.  Membrane Targeting and GTPase Activity of Rab7 Are Required for Its Ubiquitination by RNF167.

Authors:  Kim Ghilarducci; Valérie C Cabana; Ali Harake; Laurent Cappadocia; Marc P Lussier
Journal:  Int J Mol Sci       Date:  2022-07-16       Impact factor: 6.208

8.  RNF8 mediates NONO degradation following UV-induced DNA damage to properly terminate ATR-CHK1 checkpoint signaling.

Authors:  Rakesh Deshar; Wonjin Yoo; Eun-Bee Cho; Sungjoo Kim; Jong-Bok Yoon
Journal:  Nucleic Acids Res       Date:  2019-01-25       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.